A gene we thought we understood
Scientists have known for decades that a gene called APOE is tied to Alzheimer's. One version of it, called APOE ε4, is the strongest known genetic risk factor for the disease.
If you carry one copy, your risk goes up. Two copies, and the risk climbs even higher.
But here's the problem. Most of what we know about APOE ε4 comes from studies in people of European ancestry. India, with over 1.4 billion people and hundreds of distinct communities, has barely been studied.
Alzheimer's is a growing crisis in India. As life expectancy rises, more families are facing dementia in their loved ones.
Yet genetic counseling and screening tools are often based on data from other parts of the world. That means Indian families may be getting advice built on the wrong map.
Doctors can't give smart, tailored guidance if they don't know what's actually happening inside Indian genomes.
For years, researchers treated APOE ε4 rates as roughly similar across big regions. They'd quote a single "global average" and apply it broadly.
But here's the twist.
This new study shows that inside India alone, APOE ε4 rates are not just a little different. They are dramatically different from one community to another.
A country full of genetic surprises
Researchers looked at DNA from 9,524 people across 83 distinct Indian populations. This data came from a huge project called GenomeIndia.
The range they found was shocking. Some populations had an APOE ε4 frequency as low as 2.7%. Others had rates as high as 36.1%.
Think of it like this. If APOE ε4 is a lottery ticket for higher Alzheimer's risk, some communities are handing out a ticket to almost 1 in every 3 people, while others hand out tickets to just 1 in 40.
The tribal surprise
Tribal populations in India showed higher APOE ε4 rates than non-tribal groups. One tribal community in the northern coastal highlands stood out in a big way.
In that group, 36% of gene copies were the ε4 version. And 59% of the people tested carried at least one copy.
That's more than half the community carrying a known Alzheimer's risk variant.
On the other end, Tibeto-Burman populations, found mostly in the northeast, had notably lower rates.
How the gene works, in simple terms
APOE acts like a delivery truck in your body. Its main job is to carry fats, like cholesterol, around your blood and brain.
The ε4 version of the truck doesn't drive as smoothly. It can drop off fats in the wrong places, including inside the brain, where buildup may damage nerve cells over time.
The study also confirmed that ε4 carriers had different cholesterol profiles, including changes in LDL ("bad" cholesterol), HDL ("good" cholesterol), total cholesterol, and triglycerides.
So this gene isn't just about memory. It shapes how the whole body handles fat.
But there's a catch
This doesn't mean that every person in a high-risk community will develop Alzheimer's.
Genes load the gun, but lifestyle, environment, and other genes pull the trigger. Many people with ε4 never develop dementia. And many people without ε4 still do.
The gene raises risk. It does not decide fate.
Where this fits in the bigger picture
For decades, precision medicine has promised care tailored to each person. This study shows how far we still have to go, especially for underrepresented populations.
India has some of the greatest human genetic diversity on Earth. Lumping all Indians into one category, or copying European guidelines, is likely missing the mark.
Research like this is the first step toward changing that.
If you or your family is from one of these Indian communities, this study is not a reason to panic or rush into testing.
APOE genetic testing is available, but it has limits. A positive result does not mean you will get Alzheimer's. A negative result does not mean you won't.
The practical step is to talk to a doctor or a genetic counselor before testing. They can help you decide if it makes sense for you, and what to do with the results.
Lifestyle choices like exercise, sleep, managing blood pressure, and staying socially active still matter a lot, no matter your genes.
Where the study falls short
The study looked at gene frequencies, not actual dementia cases. It tells us who may be at higher risk, but not yet how that risk plays out over a lifetime.
It's also a snapshot. Long-term studies that follow these communities for years will be needed to connect the dots between genes, lifestyle, and real Alzheimer's outcomes.
And because it's published on medRxiv, a preprint site, it has not yet gone through full peer review.
Next steps include larger follow-up studies that track people over time and look at dementia rates in these populations directly.
Researchers also hope this work pushes health systems to design screening and counseling tools that reflect India's true genetic diversity. That kind of change takes years, not months, because guidelines have to catch up with the science.
But the map is finally being drawn. And for millions of Indian families, that is where better answers begin.
